Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Publication year range
1.
Gan To Kagaku Ryoho ; 29(7): 1247-50, 2002 Jul.
Article in Japanese | MEDLINE | ID: mdl-12146008

ABSTRACT

The patient was a 54-year-old woman with recurrent urinary tract cancer. A CT of the lung showed multiple nodules after bil-nephroureterectomy, cystectomy and combination chemotherapy with cisplatin (CDDP) and epirubicin (EPI). As second line chemotherapy for the patient, TXL was administered. She was hemodialized after operation, and there are few reports about paclitaxel (TXL) therapy for hemodialysis (HD) patients. Peak blood TXL concentration, about 1,200 ng/ml, was achieved 6 hours after the administration of TXL. The blood TXL concentration was 41 ng/ml 24 h after the administration of TXL. However, the TXL therapy was not repeated because of unacceptable neurological side effects. An almost 40% shrinkage in the size of the metastatic lung nodule was obtained after 1 cycle of treatment.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/blood , Carcinoma, Transitional Cell/drug therapy , Paclitaxel/administration & dosage , Paclitaxel/blood , Renal Dialysis , Urinary Bladder Neoplasms/drug therapy , Carcinoma, Transitional Cell/secondary , Cisplatin/pharmacology , Cystectomy , Drug Administration Schedule , Drug Resistance, Neoplasm , Feasibility Studies , Female , Humans , Kidney Failure, Chronic/therapy , Kidney Neoplasms/drug therapy , Kidney Neoplasms/secondary , Lung Neoplasms/secondary , Middle Aged , Urinary Bladder Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...